Laura L. A. Grenier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Laura L. A. Grenier has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Just Sørensen
Department of Chemistry and Nano-Science Center, University of Copenhagen, Copenhagen, Denmark
3 shared publications - Lea Gundorff Nielsen
Department of Chemistry and NanoScience Centre, University of Copenhagen, Universitetsparken 5, 2100 Copenhagen, Denmark
2 shared publications - Carolina Säll
Development ADME Novo Nordisk A/S Måløv Denmark
1 shared publication Ifeyinwa Osunkwo
Corporate Affairs and Communication, Rare Disease Novo Nordisk Zurich Switzerland
1 shared publication- Peter Bruun-Rasmussen
Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark
1 shared publication - Rune Nørgaard Rasmussen
Development ADME Novo Nordisk A/S Måløv Denmark
1 shared publication
Latest Publications
- Open Access
- 23 September 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (10) , e70732
Real‐World Claims Data on Prescribed Drugs and the Associated Drug–Drug Interaction Risk in Sickle Cell Disease in the United States
Sickle cell disease (SCD) is a debilitating hereditary hematologic disorder characterized by severe physical complications, including painful vaso‐occlusive crises, chronic pain, multi‐organ damage, and reduced life expectancy. Diverse medications are prescribed to treat SCD or manage its associated complications. However, no comprehensive resource for concomitant medication and drug–drug interaction (DDI) risk exists for people living with SCD. Here, we utilized real‐world claims data from the Merative Commercial MarketScan Research Database to identify the 100 most prescribed drugs for adolescents and adults living with SCD in the United States with commercial health insurance. DDI risks were assessed by leveraging the CERTARA Drug Interaction Database. In total, 43/100 drugs on the list were associated with DDI risks. Inhibitors were more frequently represented than inducers, suggesting that interaction risk in this population may be driven primarily by inhibition‐mediated mechanisms. CYP3A4 accounted for the largest proportion of identified interactions. The high prescription rates of the CYP3A4 substrates oxycodone (40%) and fentanyl (18.5%), associated with potentially serious clinical consequences due to DDIs, highlight the importance of considering CYP3A4 interaction risk during development of novel therapies for SCD. Overall, this analysis provides a population‐level insight into prescription patterns and subsequent DDI risks for people living with SCD. We expect these findings to (1) create clinical DDI risk awareness for this population and (2) inform strategic planning of DDI assessments during development of novel therapies indicated for SCD.
- 23 September 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (10) , e70732
Open AccessReal‐World Claims Data on Prescribed Drugs and the Associated Drug–Drug Interaction Risk in Sickle Cell Disease in the United States
Sickle cell disease (SCD) is a debilitating hereditary hematologic disorder characterized by severe physical complications, including painful vaso‐occlusive crises, chronic pain, multi‐organ damage, and reduced life expectancy. Diverse medications are prescribed to treat SCD or manage its associated complications. However, no comprehensive resource for concomitant medication and drug–drug interaction (DDI) risk exists for people living with SCD. Here, we utilized real‐world claims data from the Merative Commercial MarketScan Research Database to identify the 100 most prescribed drugs for adolescents and adults living with SCD in the United States with commercial health insurance. DDI risks were assessed by leveraging the CERTARA Drug Interaction Database. In total, 43/100 drugs on the list were associated with DDI risks. Inhibitors were more frequently represented than inducers, suggesting that interaction risk in this population may be driven primarily by inhibition‐mediated mechanisms. CYP3A4 accounted for the largest proportion of identified interactions. The high prescription rates of the CYP3A4 substrates oxycodone (40%) and fentanyl (18.5%), associated with potentially serious clinical consequences due to DDIs, highlight the importance of considering CYP3A4 interaction risk during development of novel therapies for SCD. Overall, this analysis provides a population‐level insight into prescription patterns and subsequent DDI risks for people living with SCD. We expect these findings to (1) create clinical DDI risk awareness for this population and (2) inform strategic planning of DDI assessments during development of novel therapies indicated for SCD.
- 5 December 2022
- Published by Wiley in Analysis & Sensing
- Vol. 3 (4)
Does Charge Influence the Response in Oxyanion Binding Europium(III) Complexes?
Through the synthesis of a positively charged europium complex, with a structure derived from the DO2A (1, 4, 7, 10‐tetraazacyclododecane‐1, 7‐diacetic acid), we were able to explore the influence of charge on the interaction between coordinatively unsaturated lanthanide complexes and charged oxyanions. The data suggest that the positive charge of the lanthanide host does not allow better selectivity between the differently and negatively charged oxyanion guests. Although, binding constants seem greatly improved with charge for the α‐hydroxycarboxylates investigated here.
- 5 December 2022
- Published by Wiley in Analysis & Sensing
- Vol. 3 (4)
Does Charge Influence the Response in Oxyanion Binding Europium(III) Complexes?
Through the synthesis of a positively charged europium complex, with a structure derived from the DO2A (1, 4, 7, 10‐tetraazacyclododecane‐1, 7‐diacetic acid), we were able to explore the influence of charge on the interaction between coordinatively unsaturated lanthanide complexes and charged oxyanions. The data suggest that the positive charge of the lanthanide host does not allow better selectivity between the differently and negatively charged oxyanion guests. Although, binding constants seem greatly improved with charge for the α‐hydroxycarboxylates investigated here.
- 1 September 2022
- Published by Wiley in Analysis & Sensing
- Vol. 2 (6)
Effect of Lipophilicity in Oxyanion‐Responsive Europium(III) Complexes
- 1 September 2022
- Published by Wiley in Analysis & Sensing
- Vol. 2 (6)
Effect of Lipophilicity in Oxyanion‐Responsive Europium(III) Complexes
- Open Access
- 7 July 2022
- Published by Wiley in Analysis & Sensing
- Vol. 2 (6)
Effect of Lipophilicity in Oxyanion‐Responsive Europium(III) Complexes**
Responsive lanthanide(III) complexes – europium(III) complexes in particular – have been the focus of studies for several decades. While responsive lanthanide complexes have been reported and investigated frequently, the supramolecular aspects and linear free‐energy relationship have seen less attention. Here, we are revisiting five europium(III) complexes and investigating their binding to ten different guests, all with a primary interaction between the europium(III) ion and a bidentate carboxylate anion. The studies consisted of measuring emission spectra, analysing band behaviours of the europium transitions, and calculating lifetime isotherms. The media effect was also investigated, and by eliminating the impact of hydrophobic effects, we can show that selectivity in these host‐guest systems can be tuned by the secondary lipophilic interactions.
- 7 July 2022
- Published by Wiley in Analysis & Sensing
- Vol. 2 (6)
Open AccessEffect of Lipophilicity in Oxyanion‐Responsive Europium(III) Complexes**
Responsive lanthanide(III) complexes – europium(III) complexes in particular – have been the focus of studies for several decades. While responsive lanthanide complexes have been reported and investigated frequently, the supramolecular aspects and linear free‐energy relationship have seen less attention. Here, we are revisiting five europium(III) complexes and investigating their binding to ten different guests, all with a primary interaction between the europium(III) ion and a bidentate carboxylate anion. The studies consisted of measuring emission spectra, analysing band behaviours of the europium transitions, and calculating lifetime isotherms. The media effect was also investigated, and by eliminating the impact of hydrophobic effects, we can show that selectivity in these host‐guest systems can be tuned by the secondary lipophilic interactions.